Dr. Eichenfield is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
3030 Childrens Way
San Diego, CA 92123Phone+1 858-966-6795
Education & Training
- University of Pennsylvania Health SystemResidency, Dermatology, 1988 - 1991
- Children's Hospital of PhiladelphiaResidency, Pediatrics, 1984 - 1987
- Icahn School of Medicine at Mount SinaiClass of 1984
Certifications & Licensure
- CA State Medical License 1990 - 2025
- PA State Medical License 1986 - 1992
- American Board of Dermatology Dermatology
- American Board of Dermatology Pediatric Dermatology
Awards, Honors, & Recognition
- America's Top Doctors Castle Connolly, 2004-2014
- Top Doctors:San Diego Area Castle Connolly, 2013
- Top Doctors:Southern California Castle Connolly, 2012
- Join now to see all
Clinical Trials
- Clinical Trial Comparing Tissue Adhesive Vs. Absorbable Suture Vs. Non-Absorbable Suture
- Cutivate Lotion HPA Axis Pediatric Study Start of enrollment: 2007 Jul 01
- Safety and Efficacy of LEO 80185 Topical Suspension in Adolescent Subjects (Aged 12 to 17) With Scalp Psoriasis Start of enrollment: 2010 Apr 01
- Join now to see all
Publications & Presentations
PubMed
- Functional genotype classification groups distinguish disease severity in recessive dystrophic epidermolysis bullosa.Pirunthan Pathmarajah, Edward Eid, Jaron Nazaroff, Jodi So, Vaishali Mittal
The British Journal of Dermatology. 2025-01-10 - Long-Term Safety and Efficacy with Roflumilast Cream 0.15% in Patients Aged ≥6 Years with Atopic Dermatitis: A Phase 3 Open-Label Extension Trial.Eric L Simpson, Lawrence F Eichenfield, Kim A Papp, Seth B Forman, Adelaide A Hebert
Dermatitis. 2025-01-10 - Orismilast, a PDE4B/D inhibitor, in moderate-to-severe atopic dermatitis: Efficacy and safety from a multicenter, randomized, placebo-controlled, phase 2b dose-ranging...Jonathan I Silverberg, Lawrence F Eichenfield, Andrew Blauvelt, Alan D Irvine, Emma Guttman-Yassky
The British Journal of Dermatology. 2025-01-07
Journal Articles
- Efficacy and Safety of Baricitinib Combined with Topical Corticosteroids for Treatment of Moderate to Severe Atopic DermatitisLawrence F Eichenfield, Eric L Simpson, JAMA Dermatology
- Safety and Efficacy of VP-102, a Proprietary, Drug-Device Combination Product Containing Cantharidin, 0.7% (w/v), in Children and Adults with Molluscum ContagiosumLawrence F Eichenfield, Wendy Mcfalda, Pearl Kwong, JAMA Dermatology
- Atopic Dermatitis: New DevelopmentsLawrence F Eichenfield, Allison M Han, ScienceDirect
- Join now to see all
Press Mentions
- Expert Highlights Updates in Pediatric Vitiligo CareJanuary 22nd, 2025
- A 2-Day-Old Female Presents with a Generalized Vesiculo-Erosive EruptionSeptember 17th, 2024
- Study Shows 1.5 Percent Ruxolitinib Cream Is Safe and Effective in Teenagers with EczemaJune 1st, 2024
- Join now to see all
Professional Memberships
- Fellow
- Fellow
- Fellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: